Presseinformation - 22. Oktober 2018

European Real-World Data Highlights Significant Impact of Early Intervention of Clinical Nutrition on Cancer Patient Outcomes and Care

  • Approximately 40 percent of all oncology patients in Europe are affected by malnutrition1
  • One quarter of cancer patients in Europe die from malnutrition, rather than tumor progression2
  • Baxter-sponsored research finds early clinical nutrition is associated with significant improvement in body composition in oncology patients paving the way to better tolerance to chemotherapy3
  •  

    Munich, Germany, Oct 22 – Baxter International Inc. (Baxter), a global leader in clinical nutrition, announced findings from three research studies focusing on clinical nutrition in oncology, presented at the annual industry event of the European Society for Medical Oncology (ESMO) in Munich, Germany. Investigators from France, Germany and Italy presented results on real world evidence studies around the title ‘Too little, too late. Nutrition in Oncology: An opportunity for better care’. The studies revealed that only a small fraction of malnourished cancer patients receive clinical nutrition and that early clinical nutrition in oncology could lead to significantly improved patient care.

    Approximately 40 percent of oncology patients in Europe are affected by malnutrition, and it is estimated that one out of four cancer patients die from malnutrition, rather than tumor progression. Malnutrition in oncology patients can lead to loss of skeletal muscle, increasing the risk of physical impairment, surgical complications, treatment toxicity and shorter survival.

    Focusing on clinical nutrition, Prof. Di Costanzo, Director of Medical Oncology, Careggi University Hospital, Florence, Italy, first author of the study about the real world evidence of clinical nutrition in Italian oncology patients: “Of the 69,000 metastatic cancer patients we studied, just 8.4 percent received clinical nutrition. Patient who received clinical nutrition showed significant improvement in survival compared to malnourished patients with metastasized gastrointestinal and genitourinary cancer; in addition, early clinical nutrition was associated with significant improvement in survival either in malnourished patients with metastasis and no metastasis.

    The consistent survival benefit shows there is substantial room for improving the diagnostic procedures for malnutrition, and calls for further research in this area. We believe the time has come for the oncology community to engage in defining and applying best practices about use of clinical nutrition to optimize care for cancer patients.”

    Professor Ingolf Schiefke, St. Georg Medical Center Leipzig, Germany presented real world insights on current practice of home parenteral nutrition in Germany. “Just on average 16 percent of cancer patients receive Home Parenteral Nutrition. Up to 40 percent of patients are not artificially fed display cachexia, which suggests a significant care deficiency in cancer management. On average, we found that patients who received clinical nutrition have a trend of longer survival than those who didn’t. Our findings demonstrate that the sooner clinical Nutrition is administered, the greater likelihood the patient will benefit.”

    Results from a study conducted in France, entitled ‘Malnutrition in cancer patients: is a late diagnosis a missed opportunity to improve care?’ and presented by Prof. Goldwasser, Head of Medical Oncology at Cochin University Hospital in Paris, found that patients with localised cancer with early malnutrition diagnosis had significantly fewer and shorter hospital stays than patients with a late malnutrition diagnosis for all cancer types. In metastatic cancer patients, the frequency of hospitalisations differed significantly between patients who were diagnosed early and late for all cancer types. The results showed that early diagnosis can significantly improve patient care and that early intervention must be prioritised.

    Baxter also sponsored the European Oncology Nursing Society (EONS) Satellite Symposium on 21st October at ESMO entitled ‘Teamwork for Nutrition: improving patient & clinical outcomes by addressing chemotherapy related malnutrition for patients in a multidisciplinary approach’. Highlighting the importance of collaboration among multidisciplinary teams, the Symposium aims to identify the best ways to ensure that patients and their caregivers are provided information and support to reduce chemotherapy related malnutrition; amplify their patient-led campaign on nutrition for cancer patients and giving them a voice; and highlight the different options in supportive clinical nutrition and their impact on chemotherapy-related toxicity.

    Baxter adheres to the Cancer Patient’s Bill of Rights, which includes access to nutrition services as part of care. The document is endorsed by the ECPC (European Cancer Patient Coalition) and ESSO (European Society of Surgical Oncology).

     

    About Baxter’s Global Clinical Nutrition Business

    Baxter has been assisting clinicians in treating patients' diverse nutrient needs since the 1940s, when the company first introduced liquid proteins in the form of amino acids. Since then, Baxter has continued to advance nutritional therapy. As an example, Baxter pioneered the world's first "triple-chamber system" internationally for IV nutrition, which provides many of the essential ingredients of balanced nutrition – protein, carbohydrates, lipids and electrolytes in a single container -- simplifying the preparation of parenteral nutrition for patients.

    Today, Baxter provides one of the broadest parenteral nutrition portfolios globally, which includes premix IV solutions, vitamins and lipids, as well as pharmacy workflow management, labelling and compounding technology. Baxter’s lipid emulsions are available globally in multi-chamber, ready-to-use solutions, and single solution bags that can be added to a compounded or premixed bag to ensure clinicians can prescribe the best well-balanced therapy for their individual patients.

     

    About Baxter

    Every day, millions of patients and caregivers rely on Baxter (NYSE:BAX) and its leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on TwitterLinkedIn and Facebook.

     

    Literatur:

  • 1 Hebuterne X et al., J Parenter Enteral Nutr 2014;38:196-2014. Muscaritoli M et al., Oncotarget, 2017; 8 (45): 79884-79896. Bozzetti Ann Oncol 2017; 28: 2107-2118
  • 2 Clin Nutr. 2006 Aug;25(4):563-72. Epub 2006 May 15.
  • 3 Caccialanza R et al., Supp Care Cancer 2018, in press - accepted

     

  • Media contact:

    Isabella Roth, 0039 3404701706
    isabella_roth [at] baxter.com